Abstract
Amivantamab, an epidermal growth factor receptor (EGFR)-MET bispecific antibody, is approved for the treatment of patients with advanced EGFR ex20ins NSCLC that progressed on or after platinum-based chemotherapy. We present initial real-world experience with amivantamab acquired through the global PAA program.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
